Assuming a genotypic model of inheritance, genetic markers in the LPHN2 (also known as ADGRL2) and GRIK1 genes explained much of the variability in tumor response (14% and 10.4% respectively) in our data. This evidence concerns the gene ADGRL2 and neoplasm.